+298.9%
PDD vs MRNA
+561.6%
-262.7%
-87.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.7% | -2.2% | +2.9% | +0.9% |
| 7D | -4.1% | +5.5% | -9.5% | -4.6% |
| 30D | -9.6% | +158.7% | -168.3% | -24.5% |
| 3M | -4.3% | +182.1% | -186.4% | -21.9% |
| 6M | -18.8% | +151.8% | -170.6% | -32.9% |
| YTD | -27.5% | +393.6% | -421.1% | -46.9% |
| 1Y | -33.6% | +499.5% | -533.1% | -53.5% |
| 3Y | -20.4% | +29.3% | -49.7% | -31.9% |
| 5Y | -19.6% | -65.1% | +45.5% | -23.1% |
| All | +298.9% | +561.6% | -262.7% | +249.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling